The human brain has some remarkable capabilities – including the ability to block cancer drugs from effectively reaching cancer cells in the brain.
The greatest obstacle when it comes to treating cancer that has spread to the brain is the blood-brain barrier, the brain’s natural defence mechanism that is a collection of blood vessels that can filter out what goes in and out of the brain.
Purdue University scientists have provided the first comprehensive characterisation of both the blood-brain and blood-tumour barriers in brain metastases of lung cancer, which will serve as a road map for treatment development.
The work was recently published in Oncotarget.
The research was led by Tiffany Lyle, assistant professor of veterinary anatomic pathology, whose work focuses on the pathology of the blood-brain barrier.
As the principal investigator of the Comparative Blood-Brain Barrier Laboratory, she and her team have collaborated with scientists at Purdue and the Indiana University Simon Cancer Center.
“Brain metastases occur most frequently in patients diagnosed with breast and lung cancer and melanoma,” Lyle said. “These metastases have a devastating survival rate, mostly because it’s so difficult to get drugs into the brain tissue because of the blood-brain barrier.”
Brain metastases, or secondary brain tumours, occur when cancer cells spread from their original site to the brain.
This happens in 10% to 30% of adults with cancer, according to the Mayo Clinic.
When cancer cells invade the brain, the blood-brain barrier transitions into the blood-tumour barrier, and this transition still presents a roadblock for effective drug delivery to the brain.
The formation of the blood-tumour barrier has been insufficiently characterised in lung cancer until now, Lyle said.
“We wanted to see what changes in the blood-brain barrier were occurring rapidly and which ones were sustained over time,” Lyle said.
“Identifying those changes and pinpointing when they occur during the transition will be critical to developing treatment plans and being able to identify where, and when, cancer cells need to be targeted.”
The blood-brain and blood-tumour barriers were analysed in animal models with non-small-cell cancer cells and immunofluorescent imaging.
Researchers also validated their findings by studying the blood-tumour barrier of brain metastases in human post-mortem tissue.
Scientists observed that one of the sustained changes during the transition from the blood-brain barrier to the blood-tumour barrier was in one of the largest cell types in the brain that has numerous functions.
These cells are known as astrocytes. Lyle said that discovery alone will be key when it comes to future treatment development.
“Identifying when that change occurs during the transition is critical because it tells us when and where the brain vasculature prevents effective drug delivery,” Lyle said.
Lyle also heads the Comparative Blood-Brain Barrier Laboratory at Purdue and is already collaborating with Yoon Yeo, a professor in the Department of Industrial and Physical Pharmacy, to work on improving drug delivery.
Being able to truly target cancer drugs to diseased tissue could improve quality of life in patients, Lyle said.
“A goal of our research is to meaningfully contribute to the evolving field of personalised medicine and provide patients who have received a devastating diagnosis a sense of hope for treatment possibilities,” Lyle said.
Source: Purdue University